Investigational drug · Phase 2
SYS6090
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC - Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "SYS6090"
First trial start
2026
Feb 28, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6090", any sponsor or status.
Conditions studied
As listed on its trial records.
- HCC - Hepatocellular Carcinoma
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Unresectable Advanced or Metastatic Colorectal Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6090" as an intervention, largest first.
- SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07472647 · 596 participants (planned) · Start Feb 28, 2026 · Primary completion Feb 28, 2029
Drug: SYS6090 + pemetrexed + platinum-based chemotherapy; SYS6090 + paclitaxel + platinum-based chemotherapy and 5 more · For: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07761286 · 288 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2029
Drug: SYS6090 Injection + Bevacizumab Injection; SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection and 1 more · For: HCC - Hepatocellular Carcinoma
Sites: Harbin, China
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07750041 · 260 participants (planned) · Start Aug 30, 2026 · Primary completion Dec 31, 2027
Drug: SYS6090 (Fixed Dose Level A) + bevacizumab; SYS6090 (Fixed Dose Level B ) + bevacizumab and 5 more · For: Unresectable Advanced or Metastatic Colorectal Cancer
Sites: Fujian, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HCC - Hepatocellular Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- AST-3424Phase 22 trials
Zhejiang Hisun Pharmaceutical Co. Ltd. · HCC - Hepatocellular Carcinoma, Advanced Solid Tumors, Hepatocellular Carcinoma
- Decoy20Phase 21 trial
Indaptus Therapeutics, Inc · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.